In a major leap for ophthalmic surgery, ForSight Robotics has completed a $125 million Series B funding round aimed at expanding its robotic surgical platform, especially for cataract and other eye procedures addressing the critical global shortage of surgeons.
Why This Matters
-
Scaling surgical capacity: With an estimated surgeon shortage projected to grow, robotics offers a scalable solution to meet rising demand.
-
Enhanced consistency & precision: ForSight’s system aims to standardise procedures, potentially improving outcomes and reducing complications.
-
Expanding access: By enabling more surgeons to operate efficiently, especially in underserved regions, access to vision-restoring surgeries could dramatically increase.
What Will the Funding Do?
The investment, co-led by Eclipse and other major backers, will:
-
Accelerate development and deployment of the ORYOM™ robot-assisted platform across ophthalmic procedures.
-
Support clinical trials and regulatory milestones.
-
Bolster team expansion—from R&D to global commercialisation
Sydney M Crago, the article’s author, shines a light on how this round sets the future direction for the company and for eye care broadly. It marks a meaningful step toward a future where more people regain sight through robotics-enhanced surgery.
By raising $125M in Series B funding, ForSight Robotics is solidifying its role in reducing the global backlog of cataract and ophthalmic surgeries through innovative robotics. This breakthrough investment highlights a future where cutting-edge technology meets widespread access to improve eye health worldwide.